Tag: pulmonary embolism
-
Rybelsus Deep Vein Thrombosis Case Report: Medical Journal, 2026
Rybelsus (Semaglutide) Associated With Significantly Increased Risk Of Blood Clots (Posted by Tom Lamb at Drug Injury Watch) In this post, we point out a recent medical journal article that discusses a Rybelsus deep vein thrombosis case…
-
Wegovy, Rybelsus, and Ozempic Blood Clots Cases Are Not Part of Federal Court MDL at This Time
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Cases involving blood clot-related injuries such as deep vein thrombosis or pulmonary embolism with the…
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…
-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…
-
Tasigna Lawsuits Federal Court MDL Order Issued in August 2021 After July 2021 JPML Hearing
Consolidation of Tasigna Drug Injury Cases Involving Atherosclerosis-related Diseases and Medical Conditions (Posted by Tom Lamb at Drug Injury Watch) On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) created a…
-
European Medicines Agency (EMA) Warns Xeljanz Increases Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Recommends That Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots As Well Aa In Patients Older Than 65 Years Of Age (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible
Serious Side Effects For Xeljanz 10 mg Dose Found In Pfizer Post-Marketing Study Leads To New European Drug Safety Regulatory Action (Posted by Tom Lamb at DrugInjuryWatch.com) The serious side effects associated…